Literature DB >> 26529069

Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection.

Young-In Kim1, Jae-Hyoung Song2, Bo-Eun Kwon2, Ha-Neul Kim3, Min-Duk Seo4, KwiSung Park5, SangWon Lee6, Sang-Gu Yeo6, Mi-Na Kweon7, Hyun-Jeong Ko8, Sun-Young Chang9.   

Abstract

Enterovirus 71 (EV71) causes hand, foot, and mouth diseases and can result in severe neurological disorders when it infects the central nervous system. Thus, there is a need for the development of effective vaccines against EV71 infection. Here we report that viral capsid protein 1 (VP1), one of the main capsid proteins of EV71, efficiently elicited VP1-specific immunoglobulin G (IgG) in the serum of mice immunized with recombinant VP1. The VP1-specific IgG produced in female mice was efficiently transferred to their offspring, conferring protection against EV71 infection immediately after birth. VP1-specific antibody can neutralize EV71 infection and protect host cells. VP1-specific maternal IgG in offspring was maintained for over 6 months. However, the pre-existence of VP1-specific maternal IgG interfered with the production of VP1-specific IgG antibody secreting cells by active immunization in offspring. Therefore, although our results showed the potential for VP1-specific maternal IgG protection against EV71 in neonatal mice, other strategies must be developed to overcome the hindrance of maternal IgG in active immunization. In this study, we developed an effective and feasible animal model to evaluate the protective efficacy of humoral immunity against EV71 infection using a maternal immunity concept.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Enterovirus 71; Maternal IgG; Pre-existing immunity; Protective immunity; VP1

Mesh:

Substances:

Year:  2015        PMID: 26529069     DOI: 10.1016/j.vaccine.2015.10.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.

Authors:  Yi-Hsuan Tsai; Sheng-Wen Huang; Wen-Sheng Hsieh; Cheng-Kai Cheng; Chuan-Fa Chang; Ya-Fang Wang; Jen-Ren Wang
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

2.  Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Ayumi Imura; Yui Sudaka; Ayako Takashino; Kanami Tamura; Kyousuke Kobayashi; Noriyo Nagata; Hidekazu Nishimura; Katsumi Mizuta; Satoshi Koike
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

3.  Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity.

Authors:  Qiang Jia; Qingyong Ng; Wenjie Chin; Tao Meng; Vincent Tak Kwong Chow; Cheng-I Wang; Jimmy Kwang; Fang He
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

Review 4.  Enterovirus 71 infection and vaccines.

Authors:  Eun-Je Yi; Yun-Ju Shin; Jeong-Hwan Kim; Tae-Gyun Kim; Sun-Young Chang
Journal:  Clin Exp Vaccine Res       Date:  2017-01-25

5.  A Functionally Different Immune Phenotype in Cattle Is Associated With Higher Mastitis Incidence.

Authors:  Karina Lutterberg; Kristina J H Kleinwort; Bernhard F Hobmaier; Stefanie M Hauck; Stefan Nüske; Armin M Scholz; Cornelia A Deeg
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

6.  Self-Assembled Multi-Epitope Peptide Amphiphiles Enhance the Immune Response against Enterovirus 71.

Authors:  Yu-Gyeong Kim; Yunsu Lee; Joo Hee Kim; Sun-Young Chang; Jong-Wha Jung; Woo-Jae Chung; Hyo-Eon Jin
Journal:  Nanomaterials (Basel)       Date:  2020-11-25       Impact factor: 5.076

7.  Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.

Authors:  Xi Wang; Ke Dong; Min Long; Fang Lin; Zhaowei Gao; Lin Wang; Zhe Zhang; Xi Chen; Ying Dai; Huiping Wang; Huizhong Zhang
Journal:  Arch Virol       Date:  2018-03-27       Impact factor: 2.574

8.  Immunogenicity and Efficacy Evaluation of Subunit Astrovirus Vaccines.

Authors:  Mehdi R M Bidokhti; Karin Ullman; Anne Sofie Hammer; Trine Hammer Jensen; Mariann Chriél; Siddappa N Byrareddy; Claudia Baule
Journal:  Vaccines (Basel)       Date:  2019-08-02

Review 9.  Insights into innate and adaptive immune responses in vaccine development against EV-A71.

Authors:  Hui Xuan Lim; Chit Laa Poh
Journal:  Ther Adv Vaccines Immunother       Date:  2019-11-21

10.  Enterovirus 71 VP1 Protein Regulates Viral Replication in SH-SY5Y Cells via the mTOR Autophagy Signaling Pathway.

Authors:  Zi-Wei Liu; Zhi-Chao Zhuang; Rui Chen; Xiao-Rui Wang; Hai-Lu Zhang; Shu-Han Li; Zhi-Yu Wang; Hong-Ling Wen
Journal:  Viruses       Date:  2019-12-20       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.